Renin-angiotensin-aldosterone system activation in long-standing type 1 diabetes.

BACKGROUND In type 1 diabetes (T1D), adjuvant treatment with inhibitors of the renin-angiotensin-aldosterone system (RAAS), which dilate the efferent arteriole, is associated with prevention of progressive albuminuria and renal dysfunction. Uncertainty still exists as to why some individuals with long-standing T1D develop diabetic kidney disease (DKD) while others do not (DKD resistors). We hypothesized that those with DKD would be distinguished from DKD resistors by the presence of RAAS activation. METHODS Renal and systemic hemodynamic function was measured before and after exogenous RAAS stimulation by intravenous infusion of angiotensin II (ANGII) in 75 patients with prolonged T1D durations and in equal numbers of nondiabetic controls. The primary outcome was change in renal vascular resistance (RVR) in response to RAAS stimulation, a measure of endogenous RAAS activation. RESULTS Those with DKD had less change in RVR following exogenous RAAS stimulation compared with DKD resistors or controls (19%, 29%, 31%, P = 0.008, DKD vs. DKD resistors), reflecting exaggerated endogenous renal RAAS activation. All T1D participants had similar changes in renal efferent arteroilar resistance (9% vs. 13%, P = 0.37) irrespective of DKD status, which reflected less change versus controls (20%, P = 0.03). In contrast, those with DKD exhibited comparatively less change in afferent arteriolar vascular resistance compared with DKD resistors or controls (33%, 48%, 48%, P = 0.031, DKD vs. DKD resistors), indicating higher endogenous RAAS activity. CONCLUSION In long-standing T1D, the intrarenal RAAS is exaggerated in DKD, which unexpectedly predominates at the afferent rather than the efferent arteriole, stimulating vasoconstriction. FUNDING JDRF operating grant 17-2013-312.

[1]  C. Kanaka-Gantenbein,et al.  Diabetic nephropathy in type 1 diabetes. , 2018, Minerva medica.

[2]  R. Guthrie Canagliflozin and cardiovascular and renal events in type 2 diabetes , 2018, Postgraduate medicine.

[3]  M. Phillip,et al.  Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[4]  P. Lapuerta,et al.  Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes , 2017, The New England journal of medicine.

[5]  J. Lovshin,et al.  Do effects of sodium–glucose cotransporter-2 inhibitors in patients with diabetes give insight into potential use in non-diabetic kidney disease? , 2017, Current opinion in nephrology and hypertension.

[6]  D. Dunger,et al.  The relationship between urinary renin-angiotensin system markers, renal function, and blood pressure in adolescents with type 1 diabetes. , 2017, American journal of physiology. Renal physiology.

[7]  S. Anderson,et al.  A Contemporary Estimate of Total Mortality and Cardiovascular Disease Risk in Young Adults With Type 1 Diabetes: The Pittsburgh Epidemiology of Diabetes Complications Study , 2016, Diabetes Care.

[8]  Lawrence A Leiter,et al.  Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. , 2016, The New England journal of medicine.

[9]  D. Maahs,et al.  The Gomez' equations and renal hemodynamic function in kidney disease research. , 2016, American journal of physiology. Renal physiology.

[10]  D. Fitchett,et al.  Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications. , 2016, Circulation.

[11]  BouletGeneviève,et al.  Prevalence of Insulin Pump Therapy and Its Association with Measures of Glycemic Control: Results from the Canadian Study of Longevity in Type 1 Diabetes , 2016 .

[12]  J. Shaw,et al.  Age-Specific Trends From 2000–2011 in All-Cause and Cause-Specific Mortality in Type 1 and Type 2 Diabetes: A Cohort Study of More Than One Million People , 2016, Diabetes Care.

[13]  Elise M. Halpern,et al.  Commonly Measured Clinical Variables Are Not Associated With Burden of Complications in Long-standing Type 1 Diabetes: Results From the Canadian Study of Longevity in Diabetes , 2016, Diabetes Care.

[14]  A. Tsapas,et al.  Empagliflozin , Cardiovascular Outcomes , and Mortality in Type 2 Diabetes , 2015 .

[15]  Connie M. Rhee,et al.  US Renal Data System 2015 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2016, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[16]  Alan B Leichtman,et al.  US Renal Data System 2014 Annual Data Report: Epidemiology of Kidney Disease in the United States. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  U. Broedl,et al.  Sodium glucose cotransport-2 inhibition and intrarenal RAS activity in people with type 1 diabetes. , 2014, Kidney international.

[18]  U. Broedl,et al.  Characterisation of glomerular haemodynamic responses to SGLT2 inhibition in patients with type 1 diabetes and renal hyperfiltration , 2014, Diabetologia.

[19]  D. Maahs,et al.  Early diabetic nephropathy in type 1 diabetes: new insights , 2014, Current opinion in endocrinology, diabetes, and obesity.

[20]  U. Broedl,et al.  Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus , 2014, Circulation.

[21]  P. Peduzzi,et al.  Combined angiotensin inhibition for the treatment of diabetic nephropathy. , 2013, The New England journal of medicine.

[22]  J. Scholey,et al.  The effect of aliskiren on urinary cytokine/chemokine responses to clamped hyperglycaemia in type 1 diabetes , 2013, Diabetologia.

[23]  A. Galecki,et al.  Uric Acid Lowering to Prevent Kidney Function Loss in Diabetes: The Preventing Early Renal Function Loss (PERL) Allopurinol Study , 2013, Current Diabetes Reports.

[24]  P. McFarlane,et al.  Chronic kidney disease in diabetes. , 2013, Canadian journal of diabetes.

[25]  Nish Chaturvedi,et al.  Cardiorenal end points in a trial of aliskiren for type 2 diabetes. , 2012, The New England journal of medicine.

[26]  Merlin C. Thomas,et al.  Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications , 2012, Journal of hypertension.

[27]  Jiang He,et al.  Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. , 2011, JAMA.

[28]  J. Scholey,et al.  The angiotensin II receptor type 2 polymorphism influences haemodynamic function and circulating RAS mediators in normotensive humans. , 2010, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[29]  Xiaoyan Wang,et al.  SDF‐1α/CXCR4 axis is involved in glucose‐potentiated proliferation and chemotaxis in rat vascular smooth muscle cells , 2010, International journal of experimental pathology.

[30]  J. Scholey,et al.  The Acute Effect of Clamped Hyperglycemia on the Urinary Excretion of Inflammatory Cytokines/Chemokines in Uncomplicated Type 1 Diabetes , 2010, Diabetes Care.

[31]  R. G. Miller,et al.  In the absence of renal disease, 20 year mortality risk in type 1 diabetes is comparable to that of the general population: a report from the Pittsburgh Epidemiology of Diabetes Complications Study , 2010, Diabetologia.

[32]  E. Abdel-Rahman,et al.  Renin-angiotensin-aldosterone system blockade effects on the kidney in the elderly: benefits and limitations. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[33]  B. Zinman,et al.  Age is a determinant of acute hemodynamic responses to hyperglycemia and angiotensin II in humans with uncomplicated type 1 diabetes mellitus. , 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

[34]  B. Zinman,et al.  Effect of Direct Renin Inhibition on Renal Hemodynamic Function, Arterial Stiffness, and Endothelial Function in Humans With Uncomplicated Type 1 Diabetes , 2009, Diabetes Care.

[35]  Edward G Lakatta,et al.  Arterial aging and subclinical arterial disease are fundamentally intertwined at macroscopic and molecular levels. , 2009, The Medical clinics of North America.

[36]  Merlin C. Thomas,et al.  The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes , 2009, Diabetes.

[37]  J. Velez The importance of the intrarenal renin–angiotensin system , 2009, Nature Clinical Practice Nephrology.

[38]  B. Zinman,et al.  Effect of Protein Kinase Cβ Inhibition on Renal Hemodynamic Function and Urinary Biomarkers in Humans With Type 1 Diabetes: A Pilot Study , 2009, Diabetes Care.

[39]  J. Scholey,et al.  Insights into the regulation of renal hemodynamic function in diabetic mellitus. , 2008, Current diabetes reviews.

[40]  G. Tangelder,et al.  Preglomerular and postglomerular basal diameter changes and reactivity to angiotensin II in obese rats , 2008, Diabetes, obesity & metabolism.

[41]  S. Yusuf,et al.  Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial , 2008, The Lancet.

[42]  B. Williams,et al.  Angiotensin II–Mediated Oxidative DNA Damage Accelerates Cellular Senescence in Cultured Human Vascular Smooth Muscle Cells via Telomere-Dependent and Independent Pathways , 2008, Circulation research.

[43]  Jennifer K. Sun,et al.  Clinical Factors Associated With Resistance to Microvascular Complications in Diabetic Patients of Extreme Disease Duration , 2007, Diabetes Care.

[44]  D. Gordin,et al.  Acute hyperglycaemia rapidly increases arterial stiffness in young patients with type 1 diabetes , 2007, Diabetologia.

[45]  A. Vinik,et al.  Diabetic Cardiovascular Autonomic Neuropathy , 2007, Circulation.

[46]  J. Scholey,et al.  Gender differences in the renal response to renin-angiotensin system blockade. , 2006, Journal of the American Society of Nephrology : JASN.

[47]  J. Scholey,et al.  Impact of renin angiotensin system modulation on the hyperfiltration state in type 1 diabetes. , 2006, Journal of the American Society of Nephrology : JASN.

[48]  E. Sochett,et al.  Gender differences in renal responses to hyperglycemia and angiotensin-converting enzyme inhibition in diabetes. , 2005, Kidney international.

[49]  J. Scholey,et al.  Endothelial nitric oxide synthase gene/gender interactions and the renal hemodynamic response to angiotensin II. , 2005, Journal of the American Society of Nephrology : JASN.

[50]  A. Reunanen,et al.  Altered Age-Related Blood Pressure Pattern in Type 1 Diabetes , 2004, Circulation.

[51]  R. Carey,et al.  The intrarenal renin–angiotensin system and diabetic nephropathy , 2003, Trends in Endocrinology & Metabolism.

[52]  A. Sved,et al.  Acute sympathoexcitatory action of angiotensin II in conscious baroreceptor-denervated rats. , 2002, American journal of physiology. Regulatory, integrative and comparative physiology.

[53]  G. Crepaldi,et al.  Nitric oxide modulation of renal and cardiac hemodynamics in type 2 diabetes. , 2002, European journal of endocrinology.

[54]  Michael E. Miller,et al.  Cellular basis of diabetic nephropathy: 1. Study design and renal structural-functional relationships in patients with long-standing type 1 diabetes. , 2002, Diabetes.

[55]  J. Floras,et al.  Variation in the renin angiotensin system throughout the normal menstrual cycle. , 2002, Journal of the American Society of Nephrology : JASN.

[56]  M. Emoto,et al.  Diabetes mellitus Worsens Intrarenal Hemodynamic Abnormalities in Nondialyzed Patients with Chronic Renal Failure , 2000, Nephron.

[57]  N. Hollenberg,et al.  The paradox of the low-renin state in diabetic nephropathy. , 1999, Journal of the American Society of Nephrology : JASN.

[58]  J. Miller,et al.  Impact of hyperglycemia on the renin angiotensin system in early human type 1 diabetes mellitus. , 1999, Journal of the American Society of Nephrology : JASN.

[59]  F. Logerfo,et al.  Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia. , 1998, Journal of vascular surgery.

[60]  B. Zinman,et al.  Effect of hyperglycaemia on arterial pressure, plasma renin activity and renal function in early diabetes. , 1996, Clinical science.

[61]  A. Krolewski,et al.  Genetic Predisposition to Diabetic Nephropathy: Evidence for a Role of the Angiotensin I–Converting Enzyme Gene , 1994, Diabetes.

[62]  J. Flier,et al.  Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. , 1987, The New England journal of medicine.

[63]  B. Brenner,et al.  Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. , 1986, The Journal of clinical investigation.

[64]  D. Gómez,et al.  Evaluation of renal resistances, with special reference to changes in essential hypertension. , 1951, The Journal of clinical investigation.

[65]  N. Chavez-Tapia,et al.  Diabetic cardiovascular autonomic neuropathy : A review , 2017 .

[66]  H. Parving,et al.  Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. , 2016, The New England journal of medicine.

[67]  R. Beck Glycemic control and excess mortality in type 1 diabetes. , 2015, The New England journal of medicine.

[68]  D. Maahs,et al.  Update on Estimation of Kidney Function in Diabetic Kidney Disease , 2015 .

[69]  Lawrence A Leiter,et al.  Canadian Diabetes Association Clinical Practice Guidelines Expert Committee , 2013 .

[70]  E. Lewis,et al.  Pyridorin in type 2 diabetic nephropathy. , 2012, Journal of the American Society of Nephrology : JASN.

[71]  B. Zinman,et al.  Systemic hemodynamic function in humans with type 1 diabetes treated with protein kinase Cβ inhibition and renin-angiotensin system blockade: a pilot study. , 2012, Canadian journal of physiology and pharmacology.

[72]  J. Tamsma,et al.  Renal and retinal effects of enalapril and losartan in type 1 diabetes. , 2009, The New England journal of medicine.

[73]  N. Hollenberg,et al.  Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus. , 2003, Kidney international.

[74]  D. Cattran,et al.  Impact of gender on the renal response to angiotensin II. , 1999, Kidney international.

[75]  J. Wetzels,et al.  The changing natural history of nephropathy in type I diabetes. , 1986, The American journal of medicine.